×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRSP – crispr therapeutics ag - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRSP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
10:31 am
crsp
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]
Low
Report
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy [Seeking Alpha]
12/2
02:16 pm
crsp
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]
Low
Report
CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors [Seeking Alpha]
12/1
05:37 am
crsp
What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]
Low
Report
What CRISPR Therapeutics' (CRSP) Latest Trial Results Mean for Investors [Yahoo! Finance]
11/29
04:21 pm
crsp
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
CRISPR Therapeutics (CRSP): Assessing Valuation in Light of Recent Share Price Volatility [Yahoo! Finance]
11/29
01:13 pm
crsp
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]
Medium
Report
Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown [Yahoo! Finance]
11/26
07:02 am
crsp
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $74.00 price target on by analysts at Chardan Capital.
Low
Report
CRISPR Therapeutics (NASDAQ:CRSP) was given a new $74.00 price target on by analysts at Chardan Capital.
11/25
08:51 am
crsp
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance [Yahoo! Finance]
Medium
Report
Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance [Yahoo! Finance]
11/19
07:38 pm
crsp
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? [Yahoo! Finance]
Medium
Report
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First? [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
12:26 pm
crsp
Form SCHEDULE 13G CRISPR Therapeutics AG Filed by: ORBIS INVESTMENT MANAGEMENT LTD
Low
Report
Form SCHEDULE 13G CRISPR Therapeutics AG Filed by: ORBIS INVESTMENT MANAGEMENT LTD
11/10
08:16 am
crsp
Form 10-Q CRISPR Therapeutics AG For: Sep 30
Medium
Report
Form 10-Q CRISPR Therapeutics AG For: Sep 30
11/10
08:10 am
crsp
Form 8-K CRISPR Therapeutics AG For: Nov 10
Medium
Report
Form 8-K CRISPR Therapeutics AG For: Nov 10
11/4
04:48 pm
crsp
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ARK Investment Management LLC
Low
Report
Form SCHEDULE 13G/A CRISPR Therapeutics AG Filed by: ARK Investment Management LLC
10/20
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Kulkarni Samarth
Low
Report
Form 4 CRISPR Therapeutics AG For: Oct 16 Filed by: Kulkarni Samarth
10/20
01:02 pm
crsp
Form 424B5 CRISPR Therapeutics AG
Low
Report
Form 424B5 CRISPR Therapeutics AG
10/15
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 13 Filed by: KASINGER JAMES R.
Medium
Report
Form 4 CRISPR Therapeutics AG For: Oct 13 Filed by: KASINGER JAMES R.
10/15
05:35 pm
crsp
Form 4 CRISPR Therapeutics AG For: Oct 13 Filed by: Kulkarni Samarth
Medium
Report
Form 4 CRISPR Therapeutics AG For: Oct 13 Filed by: Kulkarni Samarth
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
CRISPR Therapeutics down 4% premarket on initial CTX001 data [Seeking Alpha]
19.1%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
2/28 Can CRISPR Therapeutics Double Your Money in 2020? [The Motley Fool] 13.1%
10/28 Q3/2019 9/30/2019 EPS 2.400 ZacksConsensus N/A ActVsEst N/A - N/A 12.5%
8/5 Form 4 CRISPR Therapeutics AG For: Aug 01 Filed by: Ho Tony W 7.5%
2/7 First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results [The Motley Fool] 6.8%
12/2 Form 4 CRISPR Therapeutics AG For: Dec 01 Filed by: Kulkarni Samarth 6.3%
11/22 Form 8-K CRISPR Therapeutics AG For: Nov 19 6.1%
10/30 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 5.9%
6/6 Form 8-K CRISPR Therapeutics AG For: Jun 06 5.6%
4/24 Form DEF 14A CRISPR Therapeutics AG For: Jun 11 5.5%
TOP News Decliners
11/20
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-10.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
3/31 Form 8-K CRISPR Therapeutics AG For: Mar 31 -10.4%
8/3 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -10.2%
12/27 Form 8-K CRISPR Therapeutics AG For: Dec 27 -7.5%
12/6 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Wells Fargo & Co. -7.1%
2/21 Crispr Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -6.5%
10/1 CRISPR Therapeutics to Present at Upcoming Investor Conferences -6.3%
9/25 Is CRISPR Therapeutics a Buy? [The Motley Fool] -5.9%
2/13 Crispr Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock. -5.6%
6/19 Form 4 CRISPR Therapeutics AG For: Jun 17 Filed by: Kulkarni Samarth -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: